Lys29-linkage of ASK1 by Skp1−Cullin 1−Fbxo21 ubiquitin ligase complex is required for antiviral innate response

  1. Zhou Yu
  2. Taoyong Chen  Is a corresponding author
  3. Xuelian Li
  4. Mingjin Yang
  5. Songqing Tang
  6. Xuhui Zhu
  7. Yan Gu
  8. Xiaoping Su
  9. Meng Xia
  10. Weihua Li
  11. Xuemin Zhang
  12. Qingqing Wang
  13. Xuetao Cao
  14. Jianli Wang
  1. Institute of Immunology, China
  2. National Key Laboratory of Medical Immunology and Institute of Immunology, China
  3. National Key Laboratory of Medical Molecular Biology and Department of Immunology, China
  4. Institute of Basic Medical Sciences, China
  5. Zhejiang University School of Medicine, China

Abstract

Protein ubiquitination regulated by ubiquitin ligases plays important roles in innate immunity. However, key regulators of ubiquitination during innate response and roles of new types of ubiquitination (apart from Lys48- and Lys63-linkage) in control of innate signaling have not been clearly understood. Here we report that F-box only protein Fbxo21, a functionally unknown component of SCF (Skp1-Cul1-F-box protein) complex, facilitates Lys29-linkage and activation of ASK1 (apoptosis signal-regulating kinase 1), and promotes type I interferon production upon viral infection. Fbxo21 deficiency in mice cells impairs virus-induced Lys29-linkage and activation of ASK1, attenuates c-Jun N-terminal kinase (JNK) and p38 signaling pathway, and decreases the production of proinflammatory cytokines and type I interferon, resulting in reduced antiviral innate response and enhanced virus replication. Therefore Fbxo21 is required for ASK1 activation via Lys29-linkage of ASK1 during antiviral innate response, providing mechanistic insights into non-proteolytic roles of SCF complex in innate immune response.

Article and author information

Author details

  1. Zhou Yu

    Zhejiang University School of Medicine, Institute of Immunology, Hangzhou, China
    Competing interests
    No competing interests declared.
  2. Taoyong Chen

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    For correspondence
    chenty@immunol.org
    Competing interests
    No competing interests declared.
  3. Xuelian Li

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    Competing interests
    No competing interests declared.
  4. Mingjin Yang

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    Competing interests
    No competing interests declared.
  5. Songqing Tang

    Zhejiang University School of Medicine, Institute of Immunology, Hangzhou, China
    Competing interests
    No competing interests declared.
  6. Xuhui Zhu

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    Competing interests
    No competing interests declared.
  7. Yan Gu

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    Competing interests
    No competing interests declared.
  8. Xiaoping Su

    Second Military Medical University, National Key Laboratory of Medical Immunology and Institute of Immunology, Shanghai, China
    Competing interests
    No competing interests declared.
  9. Meng Xia

    Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, National Key Laboratory of Medical Molecular Biology and Department of Immunology, Beijing, China
    Competing interests
    No competing interests declared.
  10. Weihua Li

    National Center of Biomedical Analysis, Institute of Basic Medical Sciences, Beijing, China
    Competing interests
    No competing interests declared.
  11. Xuemin Zhang

    National Center of Biomedical Analysis, Institute of Basic Medical Sciences, Beijing, China
    Competing interests
    No competing interests declared.
  12. Qingqing Wang

    Zhejiang University School of Medicine, Institute of Immunology, Hangzhou, China
    Competing interests
    No competing interests declared.
  13. Xuetao Cao

    National Key Laboratory of Medical Immunology and Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, China
    Competing interests
    Xuetao Cao, Reviewing editor, eLife.
  14. Jianli Wang

    Zhejiang University School of Medicine, Institute of Immunology, Hangzhou, China
    Competing interests
    No competing interests declared.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and was approved by the Scientific Investigation Board of Second Military Medical University, Shanghai (Case No. SMMU-2015-0067).

Copyright

© 2016, Yu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,576
    views
  • 714
    downloads
  • 50
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zhou Yu
  2. Taoyong Chen
  3. Xuelian Li
  4. Mingjin Yang
  5. Songqing Tang
  6. Xuhui Zhu
  7. Yan Gu
  8. Xiaoping Su
  9. Meng Xia
  10. Weihua Li
  11. Xuemin Zhang
  12. Qingqing Wang
  13. Xuetao Cao
  14. Jianli Wang
(2016)
Lys29-linkage of ASK1 by Skp1−Cullin 1−Fbxo21 ubiquitin ligase complex is required for antiviral innate response
eLife 5:e14087.
https://doi.org/10.7554/eLife.14087

Share this article

https://doi.org/10.7554/eLife.14087

Further reading

    1. Immunology and Inflammation
    Yan Qian, Qiannv Liu ... Pengyan Xia
    Research Article

    The T6SS of Pseudomonas aeruginosa plays an essential role in the establishment of chronic infections. Inflammasome-mediated inflammatory cytokines are crucial for host defense against bacterial infections. We found that P. aeruginosa infection activates the non-canonical inflammasome in macrophages, yet it inhibits the downstream activation of the NLRP3 inflammasome. The VgrG2b of P. aeruginosa is recognized and cleaved by caspase-11, generating a free C-terminal fragment. The VgrG2b C-terminus can bind to NLRP3, inhibiting the activation of the NLRP3 inflammasome by rejecting NEK7 binding to NLRP3. Administration of a specific peptide that inhibits caspase-11 cleavage of VgrG2b significantly improves mouse survival during infection. Our discovery elucidates a mechanism by which P. aeruginosa inhibits host immune response, providing a new approach for the future clinical treatment of P. aeruginosa infections.

    1. Immunology and Inflammation
    2. Medicine
    Ole Bæk, Tik Muk ... Duc Ninh Nguyen
    Research Article

    Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity, organ damage, and altered metabolism following infection. Given the unique metabolic challenges and poor glucose regulatory capacity of preterm infants, their glucose intake during infection may have a high impact on the degree of metabolism dysregulation and organ damage. Using a preterm pig model of neonatal sepsis, we previously showed that a drastic restriction in glucose supply during infection protects against sepsis via suppression of glycolysis-induced inflammation, but results in severe hypoglycemia. Now we explored clinically relevant options for reducing glucose intake to decrease sepsis risk, without causing hypoglycemia and further explore the involvement of the liver in these protective effects. We found that a reduced glucose regime during infection increased survival via reduced pro-inflammatory response, while maintaining normoglycemia. Mechanistically, this intervention enhanced hepatic oxidative phosphorylation and possibly gluconeogenesis, and dampened both circulating and hepatic inflammation. However, switching from a high to a reduced glucose supply after the debut of clinical symptoms did not prevent sepsis, suggesting metabolic conditions at the start of infection are key in driving the outcome. Finally, an early therapy with purified human inter-alpha inhibitor protein, a liver-derived anti-inflammatory protein, partially reversed the effects of low parenteral glucose provision, likely by inhibiting neutrophil functions that mediate pathogen clearance. Our findings suggest a clinically relevant regime of reduced glucose supply for infected preterm infants could prevent or delay the development of sepsis in vulnerable neonates.